口服一些短效和长效制剂后奎尼丁血浆浓度曲线的比较。
Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.
作者信息
Frigo G M, Perucca E, Teggia-Droghi M, Gatti G, Mussini A, Salerno J
出版信息
Br J Clin Pharmacol. 1977 Aug;4(4):449-54. doi: 10.1111/j.1365-2125.1977.tb00760.x.
Abstract
1 The time-course of quinidine plasma concentrations and selected kinetic parameters were studied in healthy male volunteers given single oral doses of four different quinidine formulations. Comparison was made with quinidine sulphate in a rapidly dissolving form. 2 Plasma half-lives did not significantly differ among treatments. 3 Quinidine polygalacturonate appears to be equivalent to quinidine sulphate in respect to both the absorption and elimination kinetics. When both quinidine bisulphate (Kinidin Durules) and quinidine arabogalactansulphate (Longacor) were administered plasma levels peaked significantly later than after quinidine sulphate. However, while the former seems to be absorbed to the same extent as quinidine sulphate, the latter exhibits lower bioavailability in respect to all other preparations.
摘要
- 在健康男性志愿者中，给予四种不同奎尼丁制剂单次口服剂量后，研究了奎尼丁血浆浓度的时程和选定的动力学参数。并与快速溶解形式的硫酸奎尼丁进行了比较。2. 各治疗组间血浆半衰期无显著差异。3. 就吸收和消除动力学而言，聚半乳糖醛酸奎尼丁似乎与硫酸奎尼丁相当。当给予硫酸氢奎尼丁（金尼丁缓释片）和阿拉伯半乳糖硫酸奎尼丁（长效心复康）时，血浆水平达到峰值的时间明显晚于硫酸奎尼丁给药后。然而，虽然前者的吸收程度似乎与硫酸奎尼丁相同，但后者相对于所有其他制剂的生物利用度较低。
相似文献
1
Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.口服一些短效和长效制剂后奎尼丁血浆浓度曲线的比较。
Br J Clin Pharmacol. 1977 Aug;4(4):449-54. doi: 10.1111/j.1365-2125.1977.tb00760.x.
2
Serum quinidine levels after chronic administration of four different quinidine formulations.
J Int Med Res. 1976;4(6):393-401. doi: 10.1177/030006057600400604.
3
Enteric coated quinidine compared to sustained release preparations during repeated administration.
Acta Med Scand. 1980;207(3):183-7. doi: 10.1111/j.0954-6820.1980.tb09702.x.
4
Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent.
Arzneimittelforschung. 1977;27(9):1716-8.
5
Bioequivalence of quinidine in two sustained-release preparations.
Isr J Med Sci. 1992 Jun;28(6):357-61.
6
Comparative bioavailability characteristics of commercial quinidine polygalacturonate and sulfate tablets.
DICP. 1990 Jul-Aug;24(7-8):685-8. doi: 10.1177/106002809002400704.
7
Comparative plasma concentrations of quinidine following administration of one intramuscular and three oral formulations to 13 human subjects.向13名人体受试者分别给予一种肌肉注射制剂和三种口服制剂后，比较奎尼丁的血浆浓度。
J Pharm Sci. 1976 Sep;65(9):1325-9. doi: 10.1002/jps.2600650916.
8
Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution.
Biopharm Drug Dispos. 1982 Oct-Dec;3(4):301-10. doi: 10.1002/bdd.2510030403.
9
Quinidine dosage, with special reference to an oral loading dose schedule.奎尼丁剂量，特别涉及口服负荷剂量方案。
Br J Clin Pharmacol. 1979 Mar;7(3):293-7. doi: 10.1111/j.1365-2125.1979.tb00935.x.
10
Absolute quinidine bioavailability.
Clin Pharmacol Ther. 1976 Sep;20(3):260-5. doi: 10.1002/cpt1976203260.
引用本文的文献
1
Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study.奎尼丁或利福平治疗对人血脑屏障P-糖蛋白的调节作用：一项正电子发射断层扫描成像研究。
Drug Metab Dispos. 2015 Nov;43(11):1795-804. doi: 10.1124/dmd.114.058685. Epub 2015 Sep 9.
2
Clinical pharmacokinetics of quinidine.奎尼丁的临床药代动力学。
Clin Pharmacokinet. 1980 Mar-Apr;5(2):150-68. doi: 10.2165/00003088-198005020-00003.
3
Comparison of two long-acting forms of quinidine.两种长效奎尼丁制剂的比较。
Br J Clin Pharmacol. 1984 Jun;17(6):729-34. doi: 10.1111/j.1365-2125.1984.tb02410.x.
4
Absorption of quinidine from an enteric-coated preparation.
Eur J Clin Pharmacol. 1979 Sep;16(2):107-12. doi: 10.1007/BF00563116.
5
Divergence in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods.
J Pharmacokinet Biopharm. 1979 Jun;7(3):303-11. doi: 10.1007/BF01060020.
6
Quinidine dosage, with special reference to an oral loading dose schedule.奎尼丁剂量，特别涉及口服负荷剂量方案。
Br J Clin Pharmacol. 1979 Mar;7(3):293-7. doi: 10.1111/j.1365-2125.1979.tb00935.x.
本文引用的文献
1
THE RELATIONSHIP OF DOSAGE SCHEDULE TO THE BLOOD LEVEL OF QUINIDINE, USING ALL AVAILABLE QUINIDINE PREPARATIONS.使用所有可用的奎尼丁制剂，研究给药方案与奎尼丁血药浓度的关系。
Can Med Assoc J. 1964 Nov 7;91(19):991-6.
2
QUANTITATIVE DETERMINATION OF QUINIDINE IN PLASMA.血浆中奎尼丁的定量测定
Scand J Clin Lab Invest. 1963;15:553-6. doi: 10.1080/00365516309079786.
3
A new quinidine preparation with sustained release.一种新的缓释奎尼丁制剂。
Acta Med Scand. 1963 Apr;173:511-9. doi: 10.1111/j.0954-6820.1963.tb17435.x.
4
Factors influencing conversion of chronic atrial fibrillation with special reference to serum quinidine concentration.影响慢性心房颤动转复的因素，特别提及血清奎尼丁浓度
Circulation. 1956 Oct;14(4 Part 1):568-83. doi: 10.1161/01.cir.14.4.568.
5
Estimation of rate constants for absorption and elimination from blood concentration data.根据血药浓度数据估算吸收和消除速率常数。
J Pharm Sci. 1967 May;56(5):658-9. doi: 10.1002/jps.2600560531.
6
Method of estimating relative absorption of a drug in a series of clinical studies in which blood levels are measured after single and/or multiple doses.在一系列临床研究中估计药物相对吸收的方法，这些研究中在单次和/或多次给药后测量血药浓度。
J Pharm Sci. 1967 May;56(5):652-3. doi: 10.1002/jps.2600560527.
7
Serum quinidine concentration with two long-acting quinidine preparations.
Acta Med Scand. 1966 Apr;179(4):401-5. doi: 10.1111/j.0954-6820.1966.tb05476.x.
8
Comparison of two methods for quinidine determination and chromatographic analysis of the difference.
Clin Chim Acta. 1969 Feb;23(2):289-94. doi: 10.1016/0009-8981(69)90043-6.
9
Thin-layer chromatography for the quantitative separation of quinidine and quinidine metabolites from biological fluids and tissues.
J Chromatogr. 1968 Sep 24;37(1):70-5. doi: 10.1016/s0021-9673(01)99072-7.
10
Sustained-release quinidine (Kinidin Durules) in maintaining sinus rhythm after electroversion of atrial dysrhythmias.缓释奎尼丁（金尼丁长效片）用于心房性心律失常电复律后维持窦性心律。
Br Heart J. 1971 Mar;33(2):220-5. doi: 10.1136/hrt.33.2.220.
Zotero 插件